Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Cambrian explosion of ADCs at AACR24

Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs

April 12, 2024 10:43 PM UTC

The rapid evolution of ADC formats currently under way — sometimes referred to as the modality’s Cambrian explosion — continued full tilt at this year’s AACR meeting. Presentations showcased at least six emerging payloads, and over a dozen companies presented bispecific versions of the modality, proposing 20 different target pairs.

Success breeds success, and antibody-drug conjugates (ADCs) dominated the presentations at the 2024 American Association for Cancer Research (AACR) meeting, as companies look to expand the modality into new commercial opportunities...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article